UKPDS and the Legacy Effect
The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
The United Kingdom Prospective Diabetes Study (UKPDS) continues to produce important evidence concerning the evolution of type 2 diabetes and its management. Two studies published in this issue of the Journal provide some answers to two questions of fundamental importance to patients with diabetes and to physicians alike. In one article, Holman et al. (UKPDS 80)1 provide data that confirm a so-called legacy effect associated with intensive glucose control in patients with type 2 diabetes, long after the cessation of randomized intervention. This finding provides a fitting parallel to the observations of the Diabetes Control and Complications Trial/Epidemiology of Diabetes . . .
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Up to 25% of persons with T2D have already developed at least 1 microvascular complication by the time of diagnosis.40,41”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [40]
Citations
Cites
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397
Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes
(2005) · New England Journal of Medicine · doi:10.1056/nejmoa052187 · Cited by 5,138
Effect of a multifactorial intervention on mortality in type 2 diabetes
Gæde, P., Lund-Andersen, H., Parving, H.-H., & Pedersen, O. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0706245 · Cited by 3,465
The Role of Advanced Glycation End Products in Progression and Complications of Diabetes
Goh, S.-Y., & Cooper, M. E. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-1817 · Cited by 987
Self-citationLong-term follow-up after tight control of blood pressure in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Neil, H. A. W., & Matthews, D. R. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806359 · Cited by 762
Research works printed but not linked: 2
- 10.1056/nejmoa0806359 · DOI · Paper page
- 10.1056/nejmoa0806470 · DOI · Paper page
Cited by
Mechanisms of Diabetic Complications
Forbes, J. M., & Cooper, M. E. (2013) · Physiological Reviews · doi:10.1152/physrev.00045.2011 · Cited by 2,890
“Another possibility is “hyperglycemic memory” or a legacy effect as a result of previous episodes of hyperglycemia (83), possibly via epigenetic mechanisms including glucose-induced effects on histone modifications leading to modulation of vascular gene expression (168, 622) which persists despite a return to normogly…”
BackgroundSelf-citationThomas, M. C., Brownlee, M., Susztak, K., Sharma, K., Jandeleit-Dahm, K. A. M., Zoungas, S., Rossing, P., Groop, P.-H., & Cooper, M. E. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.18 · Cited by 1,230
Self-citationWong, T. Y., Cheung, C. M. G., Larsen, M., Sharma, S., & Simó, R. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.12 · Cited by 1,094
Low Wang, C. C., Hess, C. N., Hiatt, W. R., & Goldfine, A. B. (2016) · Circulation · doi:10.1161/circulationaha.116.022194 · Cited by 1,155
“As similar latent benefits have been seen in type 1 diabetes mellitus in the context of the DCCT(330) a “legacy effect” or “metabolic memory” has been postulated, with persistence of benefits of initial good glycemic control (and conversely, persistent adverse effects of poor glycemic control).(331,332) It has been pr…”
Laiteerapong, N., Ham, S. A., Gao, Y., Moffet, H. H., Liu, J. Y., Huang, E. S., & Karter, A. J. (2019) · Diabetes Care · doi:10.2337/dc17-1144 · Cited by 574
Brasacchio, D., Okabe, J., Tikellis, C., Balcerczyk, A., George, P., Baker, E. K., Calkin, A. C., Brownlee, M., Cooper, M. E., & El-Osta, A. (2009) · Diabetes · doi:10.2337/db08-1666 · Cited by 534
“These studies suggest that the injurious effects of exposure to high glucose levels persist for many years after these episodes of altered metabolic control and this is typically referred to as either “hyperglycemic memory” (3) or the legacy effect (4).”
BackgroundSelf-citationEpigenetic mechanisms in diabetic complications and metabolic memory
Reddy, M. A., Zhang, E., & Natarajan, R. (2015) · Diabetologia · doi:10.1007/s00125-014-3462-y · Cited by 496
“Other trials with type 2 diabetic patients have also found that the benefits of intensive glycaemic control lasted long after cessation of intervention, suggesting a ‘legacy effect’ [22].”
Blonde, L., Umpierrez, G. E., Reddy, S. S., McGill, J. B., Berga, S. L., Bush, M., Chandrasekaran, S., DeFronzo, R. A., Einhorn, D., Galindo, R. J., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.08.002 · Cited by 507
Edgar, L., Akbar, N., Braithwaite, A. T., Krausgruber, T., Gallart-Ayala, H., Bailey, J., Corbin, A. L., Khoyratty, T. E., Chai, J. T., Alkhalil, M., et al. (2021) · Circulation · doi:10.1161/circulationaha.120.046464 · Cited by 340
Therapies for hyperglycaemia-induced diabetic complications: from animal models to clinical trials
Calcutt, N. A., Cooper, M. E., Kern, T. S., & Schmidt, A. M. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2476 · Cited by 352
“It is also possible that irreversible vascular changes, such as advanced glycation 57 or 'hyperglycaemic memory' resulting from previous periods of hyperglycaemia 58 , could also contribute, possibly through epigenetic mechanisms such as glucoseinduced histone modifications that alter vascular gene expression [59] [60…”
BackgroundSelf-citationSchmidt, M., Dekker, F. J., & Maarsingh, H. (2013) · Pharmacological Reviews · doi:10.1124/pr.110.003707 · Cited by 267
“The metabolic disease diabetes is expected to be a leading cause of disability, morbidity, and premature mortality by the year 2030, which will severely affect both developed and developing countries (Rydén et al., 2007; Chalmers and Cooper, 2008; Danaei et al., 2011).”
BackgroundBai, Y., Cui, W., Xin, Y., Miao, X., Barati, M. T., Zhang, C., Chen, Q., Tan, Y., Cui, T., Zheng, Y., et al. (2013) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2013.01.008 · Cited by 274
Adipose tissue retains an epigenetic memory of obesity after weight loss
Hinte, L. C., Castellano-Castillo, D., Ghosh, A., Melrose, K., Gasser, E., Noé, F., Massier, L., Dong, H., Sun, W., Hoffmann, A., et al. (2024) · Nature · doi:10.1038/s41586-024-08165-7 · Cited by 269
Monocyte and macrophage immunometabolism in atherosclerosis
Groh, L., Keating, S. T., Joosten, L. A. B., Netea, M. G., & Riksen, N. P. (2018) · Seminars in Immunopathology · doi:10.1007/s00281-017-0656-7 · Cited by 248
“periodwhen patients had elevated glucose levels, which has been termed hyperglycemic memory [77] or legacy effect [78].”
Evaluating the Role of Epigenetic Histone Modifications in the Metabolic Memory of Type 1 Diabetes
Miao, F., Chen, Z., Genuth, S., Paterson, A., Zhang, L., Wu, X., Li, S. M., Cleary, P., Riggs, A., Harlan, D. M., et al. (2014) · Diabetes · doi:10.2337/db13-1251 · Cited by 253
“Similar “legacy effects” of prior strict glycemic control were also observed in the UK Prospective Diabetes Study (15,16).”
BackgroundPaneni, F., Mocharla, P., Akhmedov, A., Costantino, S., Osto, E., Volpe, M., Lüscher, T. F., & Cosentino, F. (2012) · Circulation Research · doi:10.1161/circresaha.112.266593 · Cited by 256
Novel approaches for treating diabetic retinopathy based on recent pathogenic evidence
Simó, R., & Hernández, C. (2015) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2015.04.003 · Cited by 239
“org/1 have a lower risk of micro- and macrovascular complications that persist during subsequent follow-up, even after their tight control has relented (Chalmers and Cooper, 2008; Nathan, 2014).”
BackgroundThe Scope of Coronary Heart Disease in Patients With Chronic Kidney Disease
Hage, F. G., Venkataraman, R., Zoghbi, G. J., Perry, G. J., DeMattos, A. M., & Iskandrian, A. E. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.02.047 · Cited by 247
Treatment of Diabetic Kidney Disease: Current and Future
Yamazaki, T., Mimura, I., Tanaka, T., & Nangaku, M. (2021) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2020.0217 · Cited by 237
“” Patients with past exposure to hyperglycemia have been known to develop complications, including DKD, even after treatment has normalized their blood glucose levels [8,9].”
BackgroundEpigenetic phenomena linked to diabetic complications
Pirola, L., Balcerczyk, A., Okabe, J., & El-Osta, A. (2010) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2010.188 · Cited by 239
“This phenomenon is now referred to as metabolic memory or the legacy effect”
BackgroundDiabetic kidney diseases revisited: A new perspective for a new era
Fu, H., Liu, S., Bastacky, S. I., Wang, X., Tian, X.-J., & Zhou, D. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.10.005 · Cited by 226
“com 10-year follow-up study in T2DM patients found continued benefits of intensive glycemic control on micro- and macrovascular risks and death [95,96].”
BackgroundIntensive glucose control in patients with type 2 diabetes - 15-year follow-up.
Reaven, P. D., Emanuele, N. V., Wiitala, W. L., Bahn, G. D., Reda, D. J., McCarren, M., Duckworth, W. C., & Hayward, R. A. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1806802 · Cited by 228
Pirola, L., Balcerczyk, A., Tothill, R. W., Haviv, I., Kaspi, A., Lunke, S., Ziemann, M., Karagiannis, T., Tonna, S., Kowalczyk, A., et al. (2011) · Genome Research · doi:10.1101/gr.116095.110 · Cited by 223
Large and Small Artery Cross-Talk and Recent Morbidity-Mortality Trials in Hypertension
Laurent, S., Briet, M., & Boutouyrie, P. (2009) · Hypertension · doi:10.1161/hypertensionaha.109.133116 · Cited by 217
Frederich, R., Alexander, J. H., Fiedorek, F. T., Donovan, M., Berglind, N., Harris, S., Chen, R., Wolf, R., & Mahaffey, K. W. (2010) · Postgraduate Medicine · doi:10.3810/pgm.2010.05.2138 · Cited by 217
“Asian 155 (17) 206 (16) 125 (13) 493 (15) 195 (16)”
Clinical predictive factors in diabetic kidney disease progression
Radcliffe, N. J., Seah, J., Clarke, M., MacIsaac, R. J., Jerums, G., & Ekinci, E. I. (2017) · Journal of Diabetes Investigation · doi:10.1111/jdi.12533 · Cited by 208
Metabolic memory: mechanisms and diseases
Dong, H., Sun, Y., Nie, L., Cui, A., Zhao, P., Leung, W. K., & Wang, Q. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01755-x · Cited by 214
“10,31 Hyperglycemia may increase methylation of the promoter region of sarcoplasmic/endoplasmic reticulum calcium-ATPase 2a (SERCA2a) by upregulating the expression of pro-in fl ammatory TNF-α .”
BackgroundDistinguishing Hyperglycemic Changes by Set7 in Vascular Endothelial Cells
Okabe, J., Orlowski, C., Balcerczyk, A., Tikellis, C., Thomas, M. C., Cooper, M. E., & El-Osta, A. (2012) · Circulation Research · doi:10.1161/circresaha.112.266171 · Cited by 180
Self-citationIntensive glycemic control and cardiovascular disease: an update
Brown, A., Reynolds, L. R., & Bruemmer, D. (2010) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2010.35 · Cited by 173
“This late cardiovascular benefit in the UKPDS and EDIC trial has been described as the 'legacy effect'; the existence of this effect emphasizes the importance of early intensive glycemic control, which is considered to confer so-called metabolic memory and long-term cardiovascular protection”
BackgroundEpigenetic programming, early life nutrition and the risk of metabolic disease
Block, T., & El-Osta, A. (2017) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2017.09.003 · Cited by 130
Impaired Therapeutic Capacity of Autologous Stem Cells in a Model of Type 2 Diabetes
Shin, L., & Peterson, D. A. (2012) · Stem Cells Translational Medicine · doi:10.5966/sctm.2011-0031 · Cited by 119
Edgar, L., Akbar, N., Braithwaite, A. T., Krausgruber, T., Gallart‐Ayala, H., Bailey, J. D., Corbin, A., Khoyratty, T. E., Chai, J. T., Alkhalil, M., et al. (2021) · Informationszentrum Lebenswissenschaften (ZB MED) · doi:10.1161/circulationaha.120.04646 · Cited by 113
Hill, M. D. (2014) · Handbook of clinical neurology · doi:10.1016/b978-0-444-53480-4.00012-6 · Cited by 119
“Long-term follow-up of the DCCT and UKPDS studies suggested that there may be a “legacy effect” of early aggressive treatment: patients treated early and aggressively may show a long term (>10 years) reduction in macrovascular complications of diabetes (Chalmers and Cooper, 2008).”
BackgroundGlycemic memory associated epigenetic changes
Siebel, A. L., Fernández, A. Z., & El‐Osta, A. (2010) · Biochemical Pharmacology · doi:10.1016/j.bcp.2010.06.005 · Cited by 102
Thomas, M. C., Woodward, M., Neal, B., Li, Q., Pickering, R., Marre, M., Williams, B., Perkovic, V., Cooper, M. E., Zoungas, S., et al. (2015) · Diabetes Care · doi:10.2337/dc15-0925 · Cited by 87
“This may be because of the long-lasting (legacy) effects of poor glycemic control over many years (1).”
BackgroundSelf-citationUnderstanding Metabolic Memory: A Tale of Two Studies
Miller, R. G., & Orchard, T. J. (2020) · Diabetes · doi:10.2337/db19-0514 · Cited by 89
“A similar effect has also been observed in type 2 diabetes, where it was referred to as a “legacy effect” (8,9).”
BackgroundSiddiqui, K., George, T. P., Mujammami, M. H., Isnani, A. C., & Alfadda, A. A. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1072288 · Cited by 89
“(2) Baseline level of VCAM-1was significantly associated with diabetic neuropathy, retinopathy and nephropathy.”
BackgroundInfluentialMalik, F. S., Sauder, K. A., Isom, S., Reboussin, B. A., Dabelea, D., Lawrence, J. M., Roberts, A., Mayer-Davis, E. J., Marcovina, S., Dolan, L., et al. (2022) · Diabetes Care · doi:10.2337/dc21-0507 · Cited by 80
Association Between Chlorthalidone Treatment of Systolic Hypertension and Long-term Survival
Kostis, J. B., Cabrera, J., Cheng, J. Q., Cosgrove, N. M., Deng, Y., Pressel, S. L., & Davis, B. R. (2011) · JAMA · doi:10.1001/jama.2011.1821 · Cited by 80
“This has been proposed as one explanation for the legacy effect.(8-10) Our study demonstrating this association between treatment and longterm benefits supports this hypothesis and provides a quantitative estimate of the mortality benefit.”
BackgroundImprovement in Neuropathy Outcomes With Normalizing HbA1c in Patients With Type 2 Diabetes
Ishibashi, F., Taniguchi, M., Kosaka, A., Uetake, H., & Tavakoli, M. (2018) · Diabetes Care · doi:10.2337/dc18-1560 · Cited by 86
Prattichizzo, F., de Candia, P., & Ceriello, A. (2021) · Metabolism · doi:10.1016/j.metabol.2021.154799 · Cited by 82
Wang, G., Song, X., Zhao, L., Li, Z., & Liu, B. (2018) · BioMed Research International · doi:10.1155/2018/2150218 · Cited by 82
Sara, J. D. S., Taher, R., Kolluri, N., Vella, A. V., Lerman, L. O., & Lerman, A. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0833-1 · Cited by 81
Histone methylation and vascular biology
Wei, X., Yi, X., Zhu, X., & Jiang, D. (2020) · Clinical Epigenetics · doi:10.1186/s13148-020-00826-4 · Cited by 78
Metformin, lifestyle intervention, and cognition in the Diabetes Prevention Program Outcomes Study
Luchsinger, J. A., Ma, Y., Christophi, C. A., Florez, H., Golden, S. H., Hazuda, H., Crandall, J., Venditti, E., Watson, K., Jeffries, S., et al. (2017) · Diabetes Care · doi:10.2337/dc16-2376 · Cited by 75
“Larger samples sizes may be needed to detect small differences in cognition, or a longer follow-up may be needed because of the legacy effect (35).”
BackgroundWang, H., Fang, J., Chen, F., Sun, Q., Xu, X., Lin, S., & Liu, K. (2019) · Acta Diabetologica · doi:10.1007/s00592-019-01363-0 · Cited by 81
Role of epigenetic mechanisms in the development of chronic complications of diabetes
Wegner, M., Neddermann, D., Pioruńska-Stolzmann, M., & Jagodziński, P. P. (2014) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2014.03.019 · Cited by 78
“[63] Chalmers J, Cooper ME.”
BackgroundRajasekar, P., O’Neill, C. L., Eeles, L., Stitt, A. W., & Medina, R. J. (2015) · Journal of Diabetes Research · doi:10.1155/2015/436879 · Cited by 71
“Glycemic memory is often described using diverse nomenclature such as metabolic memory [7, 8], delayed toxicity of prior chronic hyperglycemia [9], metabolic imprinting [10], latent hyperglycemic damage [11], hyperglycemic legacy effect [12], and posthyperglycemic normoglycemic damage [9] (Figure 1).”
BackgroundSyreeni, A., El-Osta, A., Forsblom, C., Sandholm, N., Parkkonen, M., Tarnow, L., Parving, H.-H., McKnight, A. J., Maxwell, A. P., Cooper, M. E., et al. (2011) · Diabetes · doi:10.2337/db11-0073 · Cited by 70
“The emerging picture is one of remarkable complexity and, in this context of various vascular complications of diabetes, the increasingly recognized phenomenon of hyperglycemic memory is perhaps the most clinically important and unsolved problem in diabetes (18).”
BackgroundSelf-citationTherapeutic potential of pro-resolving mediators in diabetic kidney disease
Vartak, T., Godson, C., & Brennan, E. P. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.113965 · Cited by 72
Extracellular microRNAs and endothelial hyperglycaemic memory: a therapeutic opportunity?
Prattichizzo, F., Giuliani, A., Nigris, V. D., Pujadas, G., Çeka, A., Sala, L. L., Genovese, S., Testa, R., Procopio, A. D., Olivieri, F., et al. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12688 · Cited by 72
“complications other than vascular) have been referred to as the ‘legacy effect’ [8].”
BackgroundA Review on Diabetic Retinopathy
Kour, V., Swain, J., Singh, J., Singh, H., & Kour, H. (2023) · Current Diabetes Reviews · doi:10.2174/0115733998253672231011161400 · Cited by 75
Menini, S., Iacobini, C., Ricci, P. C., Fantauzzi, C. B., & Pugliese, G. (2014) · Diabetologia · doi:10.1007/s00125-014-3467-6 · Cited by 68
“Altogether, our data support the hypothesis of a main role for AGEs in the ‘hyperglycaemic memory’ or ‘legacy effect’, as postulated some years ago [35], although this hypothesis is not yet proven.”
ResultDiabetes propels the risk for cardiovascular disease: sweet monocytes becoming aggressive?
van Diepen, J. A., Thiem, K., Stienstra, R., Riksen, N. P., Tack, C. J., & Netea, M. G. (2016) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-016-2316-9 · Cited by 67
“Kingdom Prospective Diabetes Study (UKPDS) trial and subsequently been defined as ‘hyperglycemic memory’ or the ‘legacy effect’ [8, 9].”
BackgroundBurns, W. C., & Thomas, M. C. (2010) · Expert Reviews in Molecular Medicine · doi:10.1017/s1462399410001481 · Cited by 66
Prattichizzo, F., de Candia, P., Nigris, V. D., Nicolucci, A., & Ceriello, A. (2020) · Metabolism · doi:10.1016/j.metabol.2020.154308 · Cited by 70
Inhibitors of Advanced Glycation End Product (AGE) Formation and Accumulation
Sourris, K. C., Watson, A. M. D., & Jandeleit-Dahm, K. A. M. (2020) · Handbook of experimental pharmacology · doi:10.1007/164_2020_391 · Cited by 66
Yu, P. C., Bosnyák, Z., & Ceriello, A. (2010) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2009.12.009 · Cited by 68
Rapp, S. R., Luchsinger, J. A., Baker, L. D., Blackburn, G. L., Hazuda, H. P., Demos‐McDermott, K. E., Jeffery, R. W., Keller, J. N., McCaffery, J. M., Pajewski, N. M., et al. (2017) · Journal of the American Geriatrics Society · doi:10.1111/jgs.14692 · Cited by 62
“For adults with metabolic disease, there is the possibility of a “legacy effect,” which refers to a significant lag time between interventions that affect metabolic process in individuals with DM and the benefits of those interventions.(30) In the U.”
BackgroundKlotho’s impact on diabetic nephropathy and its emerging connection to diabetic retinopathy
Tang, A., Zhang, Y., Wu, L., Lin, Y., Lv, L., Zhao, L., Xu, B., Huang, Y., & Li, M. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1180169 · Cited by 62
“However, the progression of DN can occur in patients who are transiently exposed to hyperglycemia, even when their glycemia is mostly controlled within the normal range by medication (6, 7).”
BackgroundAkalin, S., Berntorp, K., Ceriello, A., Das, A. K., Kilpatrick, E. S., Koblik, T., Munichoodappa, C. S., Pan, C. Y., Rosenthall, W., Shestakova, M., et al. (2009) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2009.02165.x · Cited by 60
Defining and Achieving Treatment Success in Patients With Type 2 Diabetes Mellitus
STOLAR, M. W. (2010) · Mayo Clinic Proceedings · doi:10.4065/mcp.2010.0471 · Cited by 65
Ceriello, A., Lucisano, G., Prattichizzo, F., Grotta, R. L., Frigé, C., Cosmo, S. D., Bartolo, P. D., Cianni, G. D., Fioretto, P., Giorda, C. B., et al. (2023) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2023.100666 · Cited by 63
Critical illness-induced dysglycaemia: diabetes and beyond
Smith, F. G., Sheehy, A. M., Vincent, J., & Coursin, D. B. (2010) · Critical Care · doi:10.1186/cc9266 · Cited by 57
“Th ese patients cannot be treated, and are vulnerable to short-term and long-term complications [3-5].”
Legacy effects of statins on cardiovascular and all-cause mortality: a meta-analysis
Nayak, A., Hayen, A. D., Zhu, L., McGeechan, K., Glasziou, P., Irwig, L., Doust, J. A., Gregory, G. A., & Bell, K. (2018) · BMJ Open · doi:10.1136/bmjopen-2017-020584 · Cited by 55
Xian, Y., Gao, Y., Lv, W., Ma, X., Hu, J., Chi, J., Wang, W., & Wang, Y. (2020) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-019-01777-1 · Cited by 53
Hinzmann, R., Schlaeger, C., & Tran, C. T. (2012) · International Journal of Medical Sciences · doi:10.7150/ijms.4520 · Cited by 62
“This late cardiovascular benefit has been described as the legacy effect and is believed to confer a so-called metabolic memory or long-term cardiovascular protection [87,88,97].”
BackgroundÇetinkalp, Ş., Gokce, E. H., Şimşir, I., Tanrıverdi, S. T., Doğan, F., Avcı, Ç. B., Eroğlu, İ., Utku, T., Gündüz, C., & Özer, Ö. (2020) · The International Journal of Lower Extremity Wounds · doi:10.1177/1534734620907773 · Cited by 54
Mechanisms of gut microbiota-immune-host interaction on glucose regulation in type 2 diabetes
Zhou, Y.-D., Liang, F.-X., Tian, H.-R., Luo, D., Wang, Y., & Yang, S. (2023) · Frontiers in Microbiology · doi:10.3389/fmicb.2023.1121695 · Cited by 58
“The academic community defines such residual risk of vascular complications after hypoglycemic treatment as “legacy effect” or “metabolic memory,” whose specific mechanism remains unclear (Chalmers and Cooper, 2008).”
BackgroundCorrelation of TLR4 and KLF7 in Inflammation Induced by Obesity
Wang, C., Ha, X., Li, W., Xu, P., Gu, Y., Wang, T., Wang, Y., Xie, J., & Zhang, J. (2016) · Inflammation · doi:10.1007/s10753-016-0450-z · Cited by 50
“Abdominal obesity, as one of the principal locations of the systemic inflammation response, is a risk factor for this cluster of metabolic dysfunctions that is independent of the risk conferred by overall obesity [3].”
BackgroundCooper, C. C., Reginster, J., Cortet, B., Díaz Curiel, M., Lorenc, R. S., Kanis, J. А., & Rizzoli, R. (2012) · Current Medical Research and Opinion · doi:10.1185/03007995.2012.663750 · Cited by 55
Epigenetic Mechanisms in Diabetic Kidney Disease
Thomas, M. C. (2016) · Current Diabetes Reports · doi:10.1007/s11892-016-0723-9 · Cited by 47
Epigenetics and Type 2 Diabetes Risk
Dhawan, S., & Natarajan, R. D. (2019) · Current Diabetes Reports · doi:10.1007/s11892-019-1168-8 · Cited by 52
Kim, S. M., Lee, G., Choi, S., Kim, K., Jeong, S., Son, J. S., Yun, J., Kim, S. G., Hwang, S.-S., Park, S. Y., et al. (2020) · Diabetologia · doi:10.1007/s00125-020-05252-y · Cited by 48
Analysis of Guidelines for Screening Diabetes Mellitus in an Ambulatory Population
Sheehy, A. M., Flood, G. E., Tuan, W., Liou, J., Coursin, D. B., & Smith, M. A. (2009) · Mayo Clinic Proceedings · doi:10.4065/mcp.2009.0289 · Cited by 51
Comino, E. J., Islam, M. F., Tran, D. T., Jorm, L. R., Flack, J. R., Jalaludin, B. B., Haas, M. R., & Harris, M. (2015) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2015.02.003 · Cited by 49
“[12] Chalmers J, Cooper M.”
Diabetes Screening Among Immigrants
Creatore, M. I., Booth, G. L., Manuel, D. G., Moineddin, R., & Glazier, R. H. (2012) · Diabetes Care · doi:10.2337/dc11-1393 · Cited by 51
“In addition, periods of poor glycemic control have been shown to have long-lasting effects, further emphasizing the importance of identifying people with diabetes and asymptomatic hyperglycemia (22).”
BackgroundCell-specific epigenetic changes in atherosclerosis
Khan, A. W., Paneni, F., & Jandeleit-Dahm, K. A. M. (2021) · Clinical Science · doi:10.1042/cs20201066 · Cited by 48
Kostis, W. J., Thijs, L., Richart, T., Kostis, J. B., & Staessen, J. A. (2010) · Hypertension · doi:10.1161/hypertensionaha.110.160291 · Cited by 44
Glycemic Exposure, Glycemic Control, and Metabolic Karma in Diabetic Complications
Thomas, M. C. (2014) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2014.03.004 · Cited by 48
Monti, L. D., Galluccio, E., Villa, V., Fontana, B., Spadoni, S., & Piatti, P. M. (2017) · European Journal of Nutrition · doi:10.1007/s00394-017-1548-2 · Cited by 52
“Other trials with type 2 diabetic patients have also found that the benefits of intensive glycemic control lasted long time after cessation of intervention [48, 49].”
BackgroundShraim, B. A., Moursi, M. O., Benter, I. F., Habib, A. M., & Akhtar, S. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.701390 · Cited by 47
“This phenomenon has been described as “glycemic” or “metabolic” memory (Chalmers and Cooper, 2008; Holman et al., 2008); though recently this concept has been challenged (Miller and Orchard, 2020).”
BackgroundMechanisms of metabolic memory and renal hypoxia as a therapeutic target in diabetic kidney disease
Hirakawa, Y., Tanaka, T., & Nangaku, M. (2017) · Journal of Diabetes Investigation · doi:10.1111/jdi.12624 · Cited by 46
El-Osta, A. (2012) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e32834f319d · Cited by 42
“Since the publication of these studies, the concept of glycemic memory has received considerable attention and we now know that memory in diabetes can describe either short-term or longterm molecular and cellular changes that are a consequence of hyperglycemia [4,5].”
BackgroundPatient empowerment and optimal glycemic control
White, R. D. (2012) · Current Medical Research and Opinion · doi:10.1185/03007995.2012.677417 · Cited by 41
Dicarbonyl Stress in Diabetic Vascular Disease
Stratmann, B. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23116186 · Cited by 44
“Even after the normalisation of blood glucose levels, the increased risk remains, which has led to the assumption of a glycolytic memory (“legacy effect”) contributing to elevated morbidity and mortality in the diabetic population [1].”
BackgroundPrandi, F. R., Lecis, D., Illuminato, F., Milite, M., Celotto, R., Lerakis, S., Romeo, F., & Barillà, F. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23094589 · Cited by 42
“Prospective Diabetes Study showed that end-organ effects continued to operate >5 years after the patients had returned to their usual level of glycemic control because of the “hyperglycemic memory” or “legacy effect” [62].”
BackgroundMeier, M., & Hummel, M. (2009) · Vascular Health and Risk Management · doi:10.2147/vhrm.s4808 · Cited by 45
Epigenetic Mechanisms of Metabolic Memory in Diabetes
Jayaraman, S. (2012) · Circulation Research · doi:10.1161/circresaha.112.268375 · Cited by 41
Epigenetic modification in diabetic kidney disease
Liu, Z., Liu, J., Wang, W., An, X., Luo, L., Yu, D., & Sun, W. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1133970 · Cited by 43
“For instance, studies have found that even after a long period of strict glycemic control, patients with diabetes may still develop complications due to early high glucose (HG) exposure (4, 6, 7).”
BackgroundPeyser, A., MacHardy, N., Tarapore, F., MacHardy, J., Powell, L., Gipson, D. S., Savin, V. J., Pan, C. G., Kump, T., Vento, S., et al. (2010) · BMC Nephrology · doi:10.1186/1471-2369-11-2 · Cited by 39
“The ‘legacy” effect has been examined in studies that tested interventions to lower serum glucose concentration and blood pressure in patients with diabetes [16-18].”
BackgroundMenini, S., Iacobini, C., Fantauzzi, C. B., & Pugliese, G. (2019) · Current Medicinal Chemistry · doi:10.2174/0929867326666190711102718 · Cited by 41
Unnikrishnan, I. R., Anjana, R. M., & Mohan, V. (2011) · PubMed · Cited by 45
Metabolic Syndrome, Diabetes, Poor Cognition, and Dementia in the Caerphilly Prospective Study
Creavin, S., Gallacher, J., Bayer, A. J., Fish, M., Ebrahim, S. B. J., & Ben‐Shlomo, Y. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2011-111550 · Cited by 44
“We hypothesized that (a) metabolic syndrome was associated with intermediate risk of impaired cognition between people with and without diabetes; (b) any association between cognition and metabolic syndrome would be driven by the presence of people with diabetes in the metabolic syndrome group; and (c) metabolic syndr…”
Lipids, lipid-lowering therapy and diabetes complications
Valensi, P. E., & Picard, S. (2010) · Diabetes & Metabolism · doi:10.1016/j.diabet.2010.10.001 · Cited by 38
Epigenetic mechanisms in the pathogenesis of diabetic foot ulcers
Rafehi, H., El‐Osta, A., & Karagiannis, T. C. (2012) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2012.05.015 · Cited by 38
Lan, C.-C. E., Huang, S., Wu, C., Wu, C., & Chen, G. (2015) · Translational research · doi:10.1016/j.trsl.2015.11.002 · Cited by 38
Han, P., Gao, D., Zhang, W., Liu, S., Yang, S., & Li, X. (2015) · Life Sciences · doi:10.1016/j.lfs.2015.02.022 · Cited by 36
The Management of Type 2 Diabetic Patients with Hypoglycaemic Agents
Tsang, M.-W. (2012) · ISRN Endocrinology · doi:10.5402/2012/478120 · Cited by 40
“Its efficacy in glucose control had been well documented in UKPDS.”
BackgroundInfluentialRasmussen, B. S., Yderstræde, K. B., Carstensen, B., Skov, O., & Beck‐Nielsen, H. (2015) · Diabetologia · doi:10.1007/s00125-015-3781-7 · Cited by 36
“Screening procedures for diabetes may have implications with respect to earlier and more aggressive treatment leading to fewer complications, as demonstrated by the legacy effect found from the UK Prospective Diabetes Study [24].”
Background
Metadata
- Authors
- Chalmers, J., & Cooper, M. E.
- Affiliations
- The University of Sydney (AU)
- Baker Heart and Diabetes Institute (AU)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2008-10-09
- Volume
- 359
- Issue
- 15
- Pages
- 1618-1620
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1966627775
- Cited by
- 263
- References
- 9
- Citations by year
- 2026: 6 · 2025: 5 · 2024: 15 · 2023: 25 · 2022: 14 · 2021: 22 · 2020: 15 · 2019: 18 · 2018: 6 · 2017: 12 · 2016: 14 · 2015: 16 · 2014: 16 · 2013: 10 · 2012: 18
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- legacy effects, tight glycemic control, type 2 diabetes, long-term glycemic control, diabetes management, UKPDS
- MeSH terms
- Antihypertensive Agents, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Diabetic Angiopathies, Glycated Hemoglobin, Humans, Hypertension, Hypoglycemic Agents, Insulin, Sulfonylurea Compounds
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.